News & Trade Shows

News & Trade shows


Biomerica receives CE mark approval for home test
4/21/2009
 
Biomerica receives CE mark approval for 5-minute home test for kidney disease screening for diabetic and hypertensive individuals

Newport Beach, California – April 21, 2009 -- Biomerica, Inc. (OTC BB: BMRA) announced that it has received approval to CE mark its 5-minute home diagnostic test for detecting Microalbumin, micro amounts of albumin in urine.  Albumin is normally found in the blood and filtered by the kidneys. When the kidneys are working properly, albumin is not present in urine in significant amounts. However, when the kidneys are damaged, small amounts of albumin leak into the urine, resulting in elevated levels.  With the CE-marking, Biomerica’s new one-step test can now be marketed directly to consumers through pharmacies in the European Union. At least 40 million people in the European Union have some degree of chronic kidney disease (CKD) and that number is expected to double over the next decade, according to the European Kidney Health Alliance. Worldwide, it has been estimated that as many as 400-600 million people suffer from CKD.  The two main causes of CKD are diabetes and high blood pressure. Early detection can help prevent the progression of kidney disease to kidney failure. Nearly half of people with an advanced form of kidney disease do not know they have weak or failing kidneys, according to recent research published in the American Journal of Kidney Diseases, the official journal of the National Kidney Foundation.

“We are already in discussions with several significant distributors in Europe,” said Zackary Irani, CEO Biomerica.  “This regulatory approval allows us to now sell our new test to consumers throughout Europe.” Biomerica’s home test, which will be marketed under the trade name “FORTEL Urine Albumin Test”, is a simple five-minute test that individuals can perform in the privacy of their own home.  The test utilizes an advanced technology that requires only a sample of urine.  The FORTEL Urine Albumin Test is a part of BIOMERICA’s line of easy to use tests designed to detect diseases before they become catastrophic, incurable or too costly to treat.

About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global medical technology company, based in Newport Beach, CA.  The Company manufactures and markets advanced diagnostic products used at home, in hospitals, and in physicians’ offices for the early detection of medical conditions and diseases.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.